Evidence map›Paper›PMID 31266670›Full record

ArticleVaccine2019

Differences between coverage of yellow fever vaccine and the first dose of measles-containing vaccine: A desk review of global data sources.

Nedghie Adrien, Terri B Hyde, Marta Gacic-Dobo, Joachim Hombach, Akshaya Krishnaswamy, Philipp Lambach

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. A Systematic Review of Yellow Fever Outbreaks and Public Health Responses in Nigeria.Nigerian medical journal : journal of the Nigeria Medical Association
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nedghie AdrienGlobal Immunization Division, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
Terri B HydeGlobal Immunization Division, US Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: thyde@cdc.gov.
Marta Gacic-DoboDepartment of Immunization, Vaccines and Biologicals (IVB), WHO, Geneva, Switzerland.
Joachim HombachDepartment of Immunization, Vaccines and Biologicals (IVB), WHO, Geneva, Switzerland.
Akshaya KrishnaswamyGlobal Immunization Division, US Centers for Disease Control and Prevention, Atlanta, GA, USA; Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Philipp LambachDepartment of Immunization, Vaccines and Biologicals (IVB), WHO, Geneva, Switzerland.

Funding

Intramural CDC HHS CC999999World Health Organization 001
6 · The paper itself

Abstract

introductionThe strategy to Eliminate Yellow Fever Epidemics (EYE) is a global initiative that includes all countries with risk of yellow fever (YF) virus transmission. Of these, 40 countries (27 in Africa and 13 in the Americas) are considered high-risk and targeted for interventions to increase coverage of YF vaccine. Even though the World Health Organization (WHO) recommends that YF vaccine be given concurrently with the first dose of measles-containing vaccine (MCV1) in YF-endemic settings, estimated coverage for MCV1 and YF vaccine have varied widely. The objective of this study was to review global data sources to assess discrepancies in YF vaccine and MCV1 coverage and identify plausible reasons for these discrepancies.

methodsWe conducted a desk review of data from 34 countries (22 in Africa, 12 in Latin America), from 2006 to 2016, with national introduction of YF vaccine and listed as high-risk by the EYE strategy. Data reviewed included procured and administered doses, immunization schedules, routine coverage estimates and reported vaccine stock-outs. In the 30 countries included in the comparitive analysis, differences greater than 3 percentage points between YF vaccine and MCV1 coverage were considered meaningful.

resultsIn America, there were meaningful differences (7-45%) in coverage of the two vaccines in 6 (67%) of the 9 countries. In Africa, there were meaningful differences (4-27%) in coverage of the two vaccines in 9 (43%) of the 21 countries. Nine countries (26%) reported MVC1 stock-outs while sixteen countries (47%) reported YF vaccine stock-outs for three or more years during 2006-2016.

conclusionIn countries reporting significant differences in coverage of the two vaccines, differences may be driven by different target populations and vaccine availability. However,these were not sufficient to completely explain observed differences. Further follow-up is needed to identify possible reasons for differences in coverage rates in several countries where these could not fully be explained.

Indexed as

AfricaGlobal HealthHumansImmunization ScheduleInformation Storage and RetrievalLatin AmericaMeaslesMeasles VaccineVaccinationWorld Health OrganizationYellow FeverYellow Fever VaccineYellow fever virusMeasles VaccineYellow Fever VaccineMeasles vaccineRoutine immunization coverageStock outsYellow fever vaccine

Identifiers

PMID31266670
PMCPMC6727197

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.